Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing

Molecular Oncology

Volumn 11, Issue 2, 2017, Pages 208-219

  Schmiegel, Wolff ^a   Scott, Rodney J ^b,c,d   Dooley, Susan ^b   Lewis, Wendy ^b   Meldrum, Cliff J ^b   Pockney, Peter ^b,d   Draganic, Brian ^b,d   Smith, Steve ^b,d   Hewitt, Chelsee ^e   Philimore, Hazel ^e   Lucas, Amanda ^e   Shi, Elva ^e   Namdarian, Kateh ^e   Chan, Timmy ^e   Acosta, Danilo ^e   Ping Chang, Su ^e   Tannapfel, Andrea ^a   Reinacher Schick, Anke ^f   Uhl, Waldemar ^f   Teschendorf, Christian ^g   Wolters, Heiner ^g   Stern, Josef ^g   Viebahn, Richard ^a   Friess, Helmut ^h   Janssen, Klaus Peter ^h   Nitsche, Ulrich ^h   Slotta Huspenina, Julia ⁱ   Pohl, Michael ^a   Vangala, Deepak ^a   Baraniskin, Alexander ^a   Dockhorn Dworniczak, Barbara ^j,k   Hegewisch Becker, Susanne ^l   Ronga, Philippe ^m   Edelstein, Daniel L ⁿ   Jones, Frederick S ⁿ   Hahn, Stephan ^a   Fox, Stephen B ^e   more..

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b JOHN HUNTER HOSPITAL   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f ST JOSEF HOSPITAL   (Germany)

^g St Josefs Hospital   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j Institute of Pathology   (Germany)

^k MVZ Humangenetics and Laboratory Medicine   (Germany)

^l Haemato Oncology Hamburg   (Germany)

^m MERCK KGAA   (Germany)

ⁿ SYSMEX CORPORATION   (Japan)

more..

Author keywords

anti EGFR therapy; CRC; ctDNA; plasma; RAS mutations

Indexed keywords

DNA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; MALE; MULTICENTER STUDY; MUTATION; ONCOGENE RAS;

AGED; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85021056120     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1002/1878-0261.12023     Document Type: Article

References (54)

1. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27, 2091–2096.
2. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A and Schilsky RL (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Oncol Pract 34, 179– 185.
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626–1634.
4. Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C and Siena S (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26, 4217–4219.
5. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen Y-J, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS et al. (2014) Colon cancer, version 3.2014. J Natl Compr Cancer Netw 12, 1028–1059.
6. Bettegowda C, Sausen M, Leary R.J, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM et al. (2014) Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 6, 224ra24.
7. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski P (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22, 1535–1546.
8. Bokemeyer C, Kohne C-H, Ciardiello F, Lenz H-J, Heinemann V, Klinkhardt U, Beier F, Duecker K and Tejpar S (2014) Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 32, 5s.
9. Bokemeyer C, K€ohne C-H, Ciardiello F, Lenz H-J, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH and Tejpar S (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer Oxf Engl 51, 1243–1252.
10. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard F-C, Aura C, Saura C, Peg V et al. (2014) Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 25, 1729–1735.
11. Diaz LA and Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32, 579–586.
12. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537–540.
13. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B and Dressman D (2006) BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 3, 551–559.
14. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985–990.
15. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J et al. (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369, 1023–1034.
16. Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28, 4697–4705.
17. Dressman D, Yan H, Traverso G, Kinzler KW and Vogelstein B (2003) Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 100, 8817–8822.
18. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883–892.
19. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Lerchenmuller C, Kahl C, Seipelt G et al. (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15, 1065–1075.
20. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [WWW Document], n.d. URL http://globocan.iarc.fr/Pages/fac t_sheets_population.aspx (accessed 14 December 15).
21. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM and Ogino S (2010) NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19, 157–163.
22. Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M et al. (2010) KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. AnnSurgOncol17, 1429–1434.
23. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC et al. (2010) Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70, 5901–5911.
24. Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, Berry SR, Krahn M, Price T, Simes RJ et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357, 2040–2048.
25. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359, 1757–1765.
26. Kievit J (2002) Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur J Cancer 1990, 986–999.
27. Kim M-J, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee J-O, Bang S-M, Park KU, Kim D-W, Kang S-B et al. (2012) Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 12, 347.
28. Knijn N, Mekenkamp LJM, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JWR, Tebar M, Riemersma S, van Krieken JHJM et al. (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104, 1020–1026.
29. van Krieken JHJM, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Flejou JF, Plato Hansen T, de Hertogh G et al. (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch Int J Pathol 453, 417–431.
30. Li M, Diehl F, Dressman D, Vogelstein B and Kinzler KW (2006) BEAMing up for detection and quantification of rare sequence variants. Nat Methods 3, 95–97.
31. Longin J (2015) Review of the current status of Ras mutation testing in patients with metastatic colorectal cancer (Mcrc): flash-Ras study. Value Health J Int Soc Pharmacoeconomics Outcomes Res 18, A491.
32. Mao C, Yuan J-Q, Yang Z-Y, Fu X-H, Wu X-Y and Tang J-L (2015) Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis. Medicine (Baltimore) 94, e775.
33. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C et al. (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26, 731–736.
34. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F et al. (2014) Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). [WWW Document]. Journal of Clinical Oncology. URL http://meetinglibrary.asco.org/content/122548-143 (accessed 7 January 2016).
35. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJA et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28, 4706– 4713.
36. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J and Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22, 1201–1208.
37. Siegel RL, Miller KD and Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65, 5–29.
38. Smith G, Bounds R, Wolf H, Steele RJC, Carey FA and Wolf CR (2010) Activating K-Ras mutations outwith “hotspot” codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer 102, 693–703.
39. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA and Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26, 13–21.
40. Stroun M, Anker P, Lyautey J, Lederrey C and Maurice PA (1987) Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23, 707–712.
41. Tabernero J, Lenz H-J, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C et al. (2015) Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 16, 937–948.
42. Tabernero J, Van Cutsem E, Dıaz-Rubio E, Cervantes A, Humblet Y, Andre T, Van Laethem J-L, Soulie P, Casado E, Verslype C et al. (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25, 5225–5232.
43. Tack V, Ligtenberg MJL, Tembuyser L, Normanno N, Vander Borght S, Han van Krieken J and Dequeker EMC (2015) External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. Oncologist 20, 257–262.
44. Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BNJ, Usatoff V, Evans PM et al. (2011) KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17, 1122–1130.
45. Trojan J, Mineur L, Tomasek J, Rouleau E, Fabian P, de Maglio G, Garcıa-Alfonso P, Aprile G, Taylor A, Kafatos G et al. (2015) Panitumumab use in metastatic colorectal cancer and patterns of KRAS testing: results from a Europe-Wide Physician Survey and Medical Records Review. PLoS One 10, e0140717.
46. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 (Suppl. 3), iii1–iii9.
47. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G et al. (2009a) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408–1417.
48. Van Cutsem E, Köhne C-H, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29, 2011– 2019.
49. Van Cutsem E, Lenz H-J, Kohne C-H, Heinemann V, Tejpar S, Melezınek I, Beier F, Stroh C, Rougier P, van Krieken JH et al. (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33, 692–700.
50. Van Cutsem E, Oliveira J, ESMO Guidelines Working Group (2009b) Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl. 4), 61–63.
51. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon J-L, Van Laethem J-L, Maurel J, Richardson G et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25, 1658–1664.
52. Venook A, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O’Neil B, Shaw J, Polite B, Hochster H, Atkins J et al. (2014) O-0019calgb/Swog 80405: Phase III trial of Irinotecan/5-Fu/Leucovorin (FOLFIRI) or Oxaliplatin/5-Fu/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for patients (PTS) with KRAS wild-type (WT) untreated metastatic adenocarcinoma of the colon. Ann Oncol 25, ii112–ii113.
53. Wang S, An T, Wang J, Zhao J, Wang Z, Zhuo M, Bai H, Yang L, Zhang Y, Wang X et al. (2010) Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 16, 1324–1330.
54. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans T-J, Ismail T, Li WQ, Collins P, Ravetto P et al. (2009) A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 11, 543–552.